Macquarie Group Ltd. grew its position in shares of Allergan PLC. (NYSE:AGN) by 2.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 589,282 shares of the company’s stock after purchasing an additional 13,512 shares during the quarter. Macquarie Group Ltd. owned approximately 0.18% of Allergan PLC. worth $120,773,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Pathstone Family Office LLC increased its position in shares of Allergan PLC. by 3,327.3% during the 2nd quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after purchasing an additional 366 shares during the last quarter. Howard Hughes Medical Institute bought a new position in shares of Allergan PLC. during the 2nd quarter valued at about $103,000. Jacobi Capital Management LLC increased its position in shares of Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares during the last quarter. Massey Quick & Co. LLC increased its position in shares of Allergan PLC. by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the last quarter. Finally, Cable Hill Partners LLC increased its position in shares of Allergan PLC. by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares during the last quarter. Hedge funds and other institutional investors own 81.21% of the company’s stock.
Allergan PLC. (NYSE:AGN) traded up $0.07 on Friday, hitting $174.88. The stock had a trading volume of 2,802,315 shares, compared to its average volume of 2,909,661. The stock has a market cap of $57,550.00, a PE ratio of 11.14, a PEG ratio of 1.09 and a beta of 1.12. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan PLC. has a 52 week low of $169.61 and a 52 week high of $256.80.
Allergan PLC. (NYSE:AGN) last released its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.32 EPS. sell-side analysts predict that Allergan PLC. will post 16.28 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s payout ratio is presently -12.39%.
Allergan PLC. declared that its Board of Directors has initiated a share buyback plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/18/macquarie-group-ltd-purchases-13512-shares-of-allergan-plc-agn.html.
Several equities analysts have recently commented on AGN shares. Royal Bank Of Canada reiterated a “buy” rating and set a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Credit Suisse Group set a $243.00 price objective on Allergan PLC. and gave the company an “outperform” rating in a research report on Tuesday, October 17th. Citigroup Inc. reduced their price objective on Allergan PLC. from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday, October 19th. Cantor Fitzgerald set a $231.00 price objective on Allergan PLC. and gave the company a “hold” rating in a research report on Wednesday, November 1st. Finally, BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $246.73.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.